Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11298)
All Articles published online
|
Publishing Process of This Article
|
Mar 15, 2020 (publication date) through Nov 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d’Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol 2020; 12(3): 332-346 [PMID: 32206183 DOI: 10.4251/wjgo.v12.i3.332] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v12/i3/332.htm |
| Number | Citing Articles |
| 1 |
Tej Tummala, Ashley Sanchez Sevilla Uruchurtu, Arielle De La Cruz, Kelsey E. Huntington, Andrew George, Nicholas R. Liguori, Leiqing Zhang, Lanlan Zhou, Abbas E. Abbas, Christopher G. Azzoli, Wafik S. El-Deiry. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. Current Oncology 2023; 30(11): 9611 doi: 10.3390/curroncol30110696
|
| 2 |
Mateusz Kciuk, Beata Marciniak, Renata Kontek. Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. International Journal of Molecular Sciences 2020; 21(14): 4919 doi: 10.3390/ijms21144919
|
| 3 |
Paul D. O'Dowd, Darragh F. Sutcliffe, Darren M. Griffith. Oxaliplatin and its derivatives – An overview. Coordination Chemistry Reviews 2023; 497: 215439 doi: 10.1016/j.ccr.2023.215439
|
| 4 |
Susanna Hegewisch-Becker, Karsten Kratz-Albers, Jan Wierecky, Steffen Gerhardt, Daniel Reschke, Jens Borchardt, Ralf Reichelt, Felix Walter Friedrich. Current Treatment Landscape of Pancreatic Cancer Patients in a Network of Office-based Oncologists in Germany. Future Oncology 2022; 18(34): 3827 doi: 10.2217/fon-2022-0141
|
| 5 |
Dinara Baiskhanova, Heiner Schäfer. The Role of Nrf2 in the Regulation of Mitochondrial Function and Ferroptosis in Pancreatic Cancer. Antioxidants 2024; 13(6): 696 doi: 10.3390/antiox13060696
|
| 6 |
Xi Liu, Ana Jimenez-Alesanco, Zexian Li, Bruno Rizzuti, José L. Neira, Matías Estaras, Ling Peng, Eduardo Chuluyan, Juan Garona, Florencia Gottardo, Adrián Velazquez-Campoy, Yi Xia, Olga Abian, Patricia Santofimia-Castaño, Juan Iovanna. Development of an efficient NUPR1 inhibitor with anticancer activity. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-79340-z
|
| 7 |
Stanislav John. Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie 2022; 16(3): 127 doi: 10.36290/xon.2022.025
|
| 8 |
Jiayuan Chen, Qingling Hua, Haihong Wang, Dejun Zhang, Lei Zhao, Dandan Yu, Guoliang Pi, Tao Zhang, Zhenyu Lin. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08605-x
|